Loading
Computed Tomography / Lung Non Small Cell Carcinoma / Atezolizumab · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 3 trial comparing atezolizumab (with or without hyaluronidase) versus observation after surgical resection of stage I NSCLC, with disease-free survival as the primary endpoint. No results have been posted to the registry; the trial is actively recruiting and remains in progress.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Lung Non-Small Cell Carcinoma; age from 18 Years. Intervention: Arm B (atezolizumab). Compared with: Arm A (observation) — Active Comparator. n = 336. 36 sites: United States.
This is a registered Phase 3 trial comparing atezolizumab (with or without hyaluronidase) versus observation after surgical resection of stage I NSCLC, with disease-free survival as the primary endpoint. No results have been posted to the registry; the trial is actively recruiting and remains in progress.
This registry record contains no results, efficacy data, or safety information.
This trial addresses an important unmet need in early-stage NSCLC adjuvant therapy. Results, when available, will inform whether immunotherapy can reduce recurrence risk versus standard observation in this population.
This is a registered but actively recruiting Phase 3 trial with no results posted; the design is sound but evidence cannot yet be evaluated.
As stated by the source record.
Quoted from the source exactly as published.
This trial addresses an important unmet need in early-stage NSCLC adjuvant therapy. Results, when available, will inform whether immunotherapy can reduce recurrence risk versus standard observation in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07388524). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 336 participants (ESTIMATED). Conditions: Lung Non-Small Cell Carcinoma. Interventions: BIOLOGICAL: Atezolizumab; BIOLOGICAL: Atezolizumab and Recombinant Human Hyaluronidase; PROCEDURE: Biospecimen Collection; PROCEDURE: Computed Tomography; OTHER: Patient Observation. Primary outcome measures: Disease-free survival , From randomization to disease recurrence, second lung primary, or death, assessed up to 10 years. Brief summary: This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.